Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | 3003851 | PO / MO |
The patient forgot to take the fourth dose of Vivotif vaccine on day seven.; Case reference number US-BN-2024-000089 is a spontaneous case report initially received from other healthcare professional via Med Communication (reference number: USBAV24-0139) on 22-Jan-2024 and concerns a 19-year-old male patient. The patient's medical history and concomitant medication details were not provided. On 15-Jan-2024, the patient took the first dose of Vivotif capsule (batch number: 3003851) at an unknown dose, orally, for typhoid fever prophylaxis. As reported the patient had started the seven day series. On 17-Jan-2024, two days after receiving the first dose of Vivotif, the patient took the second dose of Vivotif capsule (batch number: 3003851) at an unknown dose, orally. On 19-Jan-2024, four days after receiving the first dose of Vivotif, the patient took the third dose of Vivotif capsule (batch number: 3003851) at an unknown dose, orally. As reported, the patient forgot to take the fourth dose of Vivotif since the patient was going on different trip and before leaving the country (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A 19-year-old male patient took three doses of Vivotif for typhoid fever prophylaxis, and reportedly forgot to take the fourth dose, which is considered as product dose omission issue. No associated adverse events were reported. Product dose omission issue is listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to Vivotif, but to a human factor. The case is non-serious.; Sender's Comments: A 19-year-old male patient took three doses of Vivotif for typhoid fever prophylaxis, and reportedly forgot to take the fourth dose, which is considered as product dose omission issue. No associated adverse events were reported. Product dose omission issue is listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to Vivotif, but to a human factor. The case is non-serious.
Comments: None.